← Browse by Condition
Medical Condition

localized prostate carcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for localized prostate carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — localized prostate carcinoma Clinical Trials

How many clinical trials are currently recruiting for localized prostate carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for localized prostate carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for localized prostate carcinoma?
localized prostate carcinoma research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a localized prostate carcinoma clinical trial?
Eligibility criteria for localized prostate carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
British Columbia Cancer Agency 1 trial
Mayo Clinic 1 trial
Georgetown University 1 trial
Baptist Health South Florida 1 trial

Recruiting Clinical Trials

NCT06200974
Recruiting
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Enrollment
100 pts
Location
Canada
Sponsor
British Columbia Cancer Agency
View Trial →
NCT06389786
Recruiting
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Enrollment
50 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT07644598 Phase 2
Recruiting
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
Enrollment
58 pts
Location
United States
Sponsor
Georgetown University
View Trial →
NCT07455903 Phase 2
Recruiting
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Enrollment
50 pts
Location
United States
Sponsor
Baptist Health South Florida
View Trial →

Related Conditions

prostate cancer (2) oligometastatic prostate carcinoma (1) stage i prostate cancer ajcc v8 (1) stage ii prostate cancer ajcc v8 (1) stage iii prostate cancer ajcc v8 (1) stage iva prostate cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology